Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical care
This symposium, co-hosted by Duke University and Cure JM Foundation on March 12, 2022, provides important information on Juvenile Myositis research.
There is no excerpt because this is a protected post.
The myositis community has reached a significant new treatment milestone. On August 27, 2026, the U.S. Food and Drug Administration approved Lisraya (brepocitinib) for adults
Cure JM’s June Virtual Summit on JIIM Research & Care convened an international panel of clinicians and researchers to cover the latest findings in JM
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.
